PJP Prophylaxis Regimens for Patients with Atovaquone and Sulfa Allergies

First-Line Alternative Options

The National Comprehensive Cancer Network recommends dapsone 100 mg daily as the most well-established alternative for patients who cannot tolerate TMP-SMX and atovaquone 1, 2
Aerosolized pentamidine 300 mg monthly administered via Respirgard II nebulizer is another effective option, as recommended by the Centers for Disease Control and Prevention 1, 2
Dapsone plus pyrimethamine plus leucovorin can be considered, particularly for patients who are also at risk for toxoplasmosis, according to the MMWR Recommendations and Reports 1

The Journal of the National Comprehensive Cancer Network recommends checking G6PD levels before initiating dapsone as G6PD deficiency increases risk of hemolytic reactions 2
Monitoring for methemoglobinemia is necessary, which can occur with dapsone therapy, as advised by the Journal of the National Comprehensive Cancer Network 2
Monitoring complete blood count with differential at initiation and monthly thereafter is recommended to assess for hematologic toxicity, according to the Journal of the National Comprehensive Cancer Network and Praxis Medical Insights 2, 3

The Centers for Disease Control and Prevention recommends that aerosolized pentamidine must be administered via the Respirgard II nebulizer specifically; other nebulization devices have not been adequately studied 1
Monthly administration in a healthcare setting is required, as recommended by the Centers for Disease Control and Prevention and Praxis Medical Insights 1, 4
Aerosolized pentamidine may be preferred for patients with neutropenia as an alternative to dapsone, according to the Blood Cancer Journal 5

The MMWR Recommendations and Reports states that all alternative agents are less effective than TMP-SMX, which remains the gold standard for PJP prophylaxis 1, 4
None of the alternative regimens provide the additional protection against common bacterial infections that TMP-SMX offers, as reported by the MMWR Recommendations and Reports 1

The Journal of the National Comprehensive Cancer Network recommends continuing prophylaxis for the duration of immunosuppression 2, 3
For HIV patients, prophylaxis should be continued until CD4+ count is >200 cells/μL for at least 3 months, as advised by the MMWR Recommendations and Reports 1
For transplant recipients, prophylaxis should be continued for at least 6-12 months post-transplantation, according to Praxis Medical Insights 3
For patients on immunosuppressive medications, prophylaxis should be continued while on significant doses of corticosteroids (≥20 mg prednisone daily or equivalent), as recommended by Praxis Medical Insights 3

The MMWR Recommendations and Reports suggests that oral clindamycin plus primaquine may be considered in unusual situations when recommended agents cannot be administered, though data on efficacy are limited 1
Intravenous trimetrexate has insufficient data to recommend as routine prophylaxis but might be considered in exceptional circumstances, as reported by the MMWR Recommendations and Reports 1